Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice

Vaccine

Volumn 29, Issue 37, 2011, Pages 6342-6351

  Wang, Saifeng ^a   Qiu, Lipeng ^a   Liu, Guangze ^b   Li, Yang ^a   Zhang, Xiaojun ^a   Jin, Wensong ^a   Gao, George F ^a   Kong, Xianping ^b   Meng, Songdong ^a  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b 458th Hospital   (China)

Author keywords

Anti HBV; Gp96; HBcAg; HBsAg; HBV transgenic mice; Hepatitis B virus; Treg

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA INTERFERON; GLYCOPROTEIN GP 96; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEPATITIS B VIRUS; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOTHERAPY; LIVER; LIVER CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL; TRANSGENIC MOUSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; HEAT-SHOCK PROTEINS; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; LIVER; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; VACCINATION;

EID: 80051569840     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.008     Document Type: Article

References (36)

1. Reyes-del Valle J., Hodge G., McChesney M.B., Cattaneo R. Protective anti-hepatitis B virus responses in rhesus monkeys primed with a vectored measles virus and boosted with a single dose of hepatitis B surface antigen. J Virol 2009, 83:9013-9017.
2. Lu F., Zhang H. Prevention of hepatitis B in China: achievements and challenges. Chin Med J 2009, 122:2925-2927.
3. Zoulim F., Locarnini S., Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009, 137:1593-1608.
4. Zheng Y., Zhao L., Wu T., Guo S., Chen Y., Zhou T. Efficacy of consensus interferon in treatment of HbeAg-positive chronic hepatitis B: a multicentre, randomized controlled trial. Virol J 2009, 6:99.
5. Webster G., Bertoletti A. Quantity and quality of virus-specific CD8 cell response: relevance to the design of a therapeutic vaccine for chronic HBV infection. Mol Immunol 2001, 38:467-473.
6. Webster G.J., Reignat S., Brown D., Ogg G.S., Jones L., Seneviratne S.L., et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004, 78:5707-5719.
7. Tan A.T., Loggi E., Boni C., Chia A., Gehring A.J., Sastry K.S., et al. Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. J Virol 2008, 82:10986-10997.
8. Inchauspé G., Michel M.L. Vaccines and immunotherapies against hepatitis B and hepatitis C viruses. J Viral Hepat 2007, 14(Suppl 1):97-103.
9. Vandepapelière P., Lau G.K., Leroux-Roels G., Horsmans Y., Gane E., Tawandee T., et al. Therapeutic HBV Vaccine Group of Investigators, Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007, 25:8585-8597.
10. Aguilar J.C., Lobaina Y., Muzio V., García D., Pentón E., Iglesias E., et al. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol Cell Biol 2004, 82:539-546.
11. Betancourt A.A., Delgado C.A., Estévez Z.C., Martínez J.C., Ríos G.V., Aureoles-Roselló S.R., et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis 2007, 11:394-401.
12. Xu D.Z., Zhao K., Guo L.M., Li L.J., Xie Q., Ren H., et al. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS ONE 2008, 3:e2565.
13. Bourgine M.M., Fontaine H., Bréchot C., Pol S., Michel M.-L. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 2006, 24:4482-4489.
14. Senturk H., Tabak F., Ozaras R., Erdem L., Canbakan B., Mert A., et al. Efficacy of pre-S-containing HBV vaccine combined with lamivudine in the treatment of chronic HBV infection. Dig Dis Sci 2009, 54:2026-2030.
15. Yang S.H., Lee C.G., Park S.H., Im S.J., Kim Y.M., Son J.M., et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther 2006, 13:1110-1117.
16. Kim C.Y., Kang E.S., Kim S.B., Kim H.E., Choi J.H., Lee D.S., et al. Increased in vivo immunological potency of HB-110, a novel therapeutic HBV DNA vaccine, by electroporation. Mol Med 2008, 40:669-676.
17. Depla E., Van der Aa A., Livingston B.D., Crimi C., Allosery K., De Brabandere V., et al. Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections. J Virol 2008, 82:435-450.
18. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2002, 2:185-194.
19. Doody A.D., Kovalchin J.T., Mihalyo M.A., Hagymasi A.T., Drake C.G., Adler A.J. Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function. J Immunol 2004, 172:6087-6092.
20. Robert J., Ramanayake T., Maniero G.D., Morales H., Chida A.S. Phylogenetic conservation of glycoprotein 96 ability to interact with CD91 and facilitate antigen cross-presentation. J Immunol 2008, 180:3176-3182.
21. Liu Z., Li X., Qiu L., Zhang X., Chen L., Cao S., et al. Treg suppress CTL responses upon immunization with HSP gp96. Eur J Immunol 2009, 39:1-11.
22. Tan A.T., Koh S., Goh V., Bertoletti A. Understanding the immunopathogenesis of chronic hepatitis B virus: an Asian prospective. J Gastroenterol Hepatol 2008, 23:833-843.
23. Manigold T., Racanelli V. T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect Dis 2007, 7:804-813.
24. Zhang Z., Zhang J.Y., Wherry E.J., Jin B., Xu B., Zou Z.S., et al. Dynamic programmed death 1 expression by virus-specific CD8T cells correlates with the outcome of acute hepatitis B. Gastroenterology 2008, 134:1938-1949.
25. Chen A., Wang L., Zhang J., Zou L., Jia Z., Zhou W., et al. H-2 Kd-restricted hepatitis B virus-derived epitope whose specific CD8+ T lymphocytes can produce gamma interferon without cytotoxicity. J Virol 2005, 79:5568-5576.
26. Sakaguchi S., Ono M., Setoguchi R., Yagi H., Hori S., Fehervari Z., et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006, 212:8-27.
27. Fu J., Xu D., Liu Z., Shi M., Zhao P., Fu B., et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007, 132:2328-2339.
28. Chen W., Shi M., Shi F., Mao Y., Tang Z., Zhang B., et al. HBcAg-pulsed dendritic cell vaccine induces Th1 polarization and production of hepatitis B virus-specific cytotoxic T lymphocytes. Hepatol Res 2009, 39:355-365.
29. Ding F.X., Wang F., Lu Y.M., Li K., Wang K.H., He X.W., et al. Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinoma. Hepatology 2009, 49:1492-1502.
30. Li H., Zhou M., Han J., Zhu X., Dong T., Gao G.F., et al. Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments. J Immunol 2005, 174:195-204.
31. Sobao Y., Sugi K., Tomiyama H., Saito S., Fujiyama S., Morimoto M., et al. Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A 2402, the most common HLA class I allele in East Asia. J Hepatol 2001, 34:922-929.
32. Bertoletti A., Gehring A.J. The immune response during hepatitis B virus infection. J Gen Virol 2006, 87:1439-1449.
33. Yan J., Liu X., Wang Y., Jiang X., Liu H., Wang M., et al. Enhancing the potency of HBV DNA vaccines using fusion genes of HBV-specific antigens and the N-terminal fragment of gp96. J Gene Med 2007, 9(2):107-121.
34. Wood C.G., Mulders P. Vitespen: a preclinical and clinical review. Future Oncol 2009, 5:763-774.
35. Bolhassani A., Zahedifard F., Taghikhani M., Rafati S. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies. Vaccine 2008, 26:3362-3370.
36. Schreiber T.H., Deyev V.V., Rosenblatt J.D., Podack E.R. Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. Cancer Res 2009, 69:2026-2033.